

From the Office of Clinical Informatics Nursing & Clinical Staff Newsletter "AMBULATORY"

Volume 1, Issue 82

January 2024

Oncology Infusion Prior Authorization Component

Optum

The **Prior Authorization** component on the Infusion Prior Authorization MPage defaults to show only the last three months of documentation. You will need to select another filter option, as shown below, to see documentation beyond three months.

errographics X	Enfusion Prior Authorization	n X Amb Nursing 2018 X	Bariabric Quick Orders X Or	ncology Quick Ordes X + 🗍 o 🖬 o 🖡 Disch						
ţ	Prior Authorization Al Visits Last 3 month Last 6 months Last 12 months 12 m									
Prior Authorization		Teday	OCT 12, 2023							
Oncology Chemotherapy		10:24	10:17	10:16						
Review	Treatment Location	TANC	TAMC	TAMC						
Staging	Insurance Carrier	Martin's Point	Martin's Point	Martin's Point						
Documents (33)	Contact Information	OPTUNI 1866572941	OPTUM 1856572941	OPTUM 18555729491						

In this issue...

Oncology Infusion Prior Authorization				
<u>Component</u>	1			
Scales and Assessment Component	1			
Acadia Inpatient Provider Note Types Updated				
Viewing Oncology Regimen Treatment Orders	2			



Scales and Assessment Component

On January 23, the Scales and Assessment component will be updated to reflect more useful data on the MPages noted below. Scales and Assessments summaries the scores and results from various tools. The update will streamline the data that populates on the workflow MPage for review and trending.

- Ambulatory 2018
- Ambulatory Pediatrics 2018
- Inpatient 2018
- Handoff

cales and Assessm	ients		 + ~	All Visits	Last 1 years	Last 2 years	Last 5 year	s ?
	JAN 05, 2024 13:23	10		12:36		12:34		12:33
ACE Score								
ASRS Total Score	-							
AUDIT Score		×.						
CRAFFT Score	-	ė.						
Current Malnutrition Sta		10						
STEADI-Feels unsteady	-	W						
STEADI-Fell in past year	-	Ł						
Total Epworth Sleepines		4						
	<	2						>

Acadia Inpatient Provider Note Types Updated

The note type names were updated for Inpatient Behavioral Health Admission and Progress Notes.

Updated Note Type Names:

- BH IP Provider Admission Note
- BH IP Provider Progress Note

Diagnoses & Probler	ns				-	
Documentation	+ Add	Display : All	~	Advanced Filters	1	
Form Browser		10.01	-		-	
Growth Chart		Arranged By: Date		Newest At Top		
		BH IP Provider Progre	ss N	01/17/2024 13:51:0	0 EST	
Health Maintenance		BH Provider Progress N	ote			
Listorical Parande Mi	-	BH IP Provider Progre	ss N	01/17/2024 13:49:2	5 EST	

As a reminder, any existing custom document search filters need to be updated to include the updated note type names.

From the Office of Clinical Informatics Nursing & Clinical Staff Newsletter – Ambulatory January 2024 Page 2 of 2

Viewing Oncology Regimen Treatment Orders

Where can I view medications the patient is receving as part of their treatment regimen?

- Medications ordered as part of the patient's treatment regimen will not appear on the medication list or medication reconciliation window, except for any prescriptions prescribed from within the regimen (i.e., oral chemotherapy, antiemetics, pre-treatment med scripts, etc.).
- When an oncology provider orders a regimen, the orders are placed in a future state so they can be activated on the day of treatment.
- There are two ways to quickly see medications that have been ordered as part of the patient's treatment regimen:
 - 1. View the **Chemotherapy** phase of the regimen(s) on the Order Profile. This includes orders for chemotherapy as well as other treatment meds: hydration, pre-meds, and antiemetics.

View	00	+ Add	to Phas	e- 010	omments				
Orders for Signature Orders for Signature Orders AIM: DOXOrubicin + ifosfamide + mesna,21D (Outpatient) (Started) ONCP AIM: DOXOrubicin (D1-3) + ifosfamide (D1-4) + mesna (D1-4),21D (Or Chemotenary (Dav 1 to 5) (Future)		ONCP AIM: DOXOrubicin (D1-3) + ifosfamide (D1-4) + mesna (D1-4),21D (Outpatient) & Last updated on: 12/19/2023 12:03 EST by: Diagnoses: Malignant (primary) neoplasm, unspecified							
- Labs (Days 1 to 4) (Future) - Imaging/Monitoring Parameters (Planned) - Scheduling (Discontinued)	~	\$		P	Component				
Clinic Scheduling and Tasks (Days 1, 3) (Future) ONC Dose Dense AC: DOXOrubicin + cycloPHOSphamide x 4 cycles (Started)					He ONCP Antiemetic Multi-Day HIGH: Aloxi Day Show Details				
ONC DOCEtaxel 60-100 (D1), 21D (Started) ONC azaCITIDine (D1-5,8-9), 28D (Started)					BONCP Antiemetic Multi-Day: Aloxi and Dex Day Show Details				
ONC darbepoetin (Aranesp) chronic kidney disease (CKD), 14D (Discontinued) ONC CARBOplatin (D1) + etoposide (D1-3), 21D (Started)					CONCP Antiemetic Multi-Day: Non-Aloxi Day Show Details				
Plans					G Chemotherapy				
- Document In Plan					🔥 Zero Hour				
Suggested Plans (0)			10	60	DOXOrubicin				
Orders			_		56 mg (25 mg/m2), Soln, IVPB, Day of Tx, Cancer, Routine, 1 Pharmacy to compound to total volume of 250mL for pump.				
Code Status Vital Signs				60	to mesna 1,140 mg = Overfill Volume (approx.) 16 mL + So. (500 mg/m2), Soln, IVPB, Day of Tx, Cancer, Routine, 12/26/2				
Activity Diet Patient Care				66	ifostamide 5,700 mg - Overfill Volume (approx.) 51 mL (2500 mg/m2), Soln, IVPB, Day of Tx, Cancer, Routine, 12/26/ Hazardous Drug				
Nursing Orders				360°	Sodium Chloride 0.9% (Sodium Chloride 0.9% (Bolus Inf. 1,000 mL, Soln, IVPB, Day of Tx, Diagnosis: Cancer, Routine,				
Medications				60	mesna 1,140 mg = Overfill Volume (approx.) 16 mL + So. (500 mg/m2), Soln, IVPB, Day of Tx, Cancer, Routine, 12/26/2				
Treatment Orders				000	nesna 2,270 mg (1000 mg/m2), Tab, TAKE HOME - ORAL, Day of Tx				
Consults Communication				-044	Patient instruction: Take at home,tablets by mouth 8 hou.				

2. In the **Medications** section of the **Orders** profile.

View	Di	played	All Active	Orders	: Ina	active (Orders Since 12/05/2023 All Orders (All	Statuses)
Clinic Scheduling and Tasks (Days 1, 3) (Future)			\$		8		Order Name	Statur
ONC Dose Dense AC: DOXOrubicin + cycloPHOSphamide x 4 cycles (Started)		00			1	_	Order Name	Status
ONC DOCEtaxel 60-100 (D1), 21D (Started)	4	Med	ications	11		-	peofiloration Not Indicated	Eutom
ONC azaCITIDine (D1-5,8-9), 28D (Started)				- 11		-00	DOCEtavel 170 esa + Overfill Volum	- Euture
ONC darbepoetin (Aranesp) chronic kidney disease (CKD), 14D (Discontinued)	11'			-	۳	100	(approx.) 31 mL + Sodium Chlorid	e ruture
ONC CARBOPIatin (DT) + etoposide (DT-3), 21D (Started)							Zero Hour	Canceler
Prioris	Þ					(a)	Antiemetic Status	Future
- Document in Plan	Þ					100°	dexAMETHasone 20 mg + Overfill .	Future
E Uncology	•					000	ondansetron (Zofran)	Future
Suggested Plans (0)	1						Zero Hour	Cancele
Orders	1					B60'	pegfilgrastim	Future
Code Status				-	-			_
Vital Signs	1					000	dexAMETHasone (Decadron)	Future
Activity	1			-		1000	palonosetron (Aloxi)	Future
Diet	•					ta	pegfilgrastim Not Indicated	Future
Patient Care	1			-		1000	DOCEtaxel 170 mg + Overfill Volum (approx.) 31 mL + Sodium Chlorid	e Future
Nursing Orders	•						Zero Hour	Cancele
Continuous Solutions	•					an I	Antiemetic Status	Future
Medications	•				.	60	dexAMETHasone 20 mg + Overfill .	Future
Laboratory	×.					60	ondansetron (Zofran)	Future
Tests/Procedures	•						Zero Hour	Cancele
Treatment Orders	1					1060	dexAMETHasone (Decadron)	Future
Consults				100	(CD.)	100		

For CI education materials or previous newsletters, please visit the CI Education portal at <u>http://ci.northernlighthealth.org/</u>